These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 28757262)

  • 1. Tofacitinib Is the Right OCTAVE for Ulcerative Colitis.
    Pouillon L; Bossuyt P; Peyrin-Biroulet L
    Gastroenterology; 2017 Sep; 153(3):862-864. PubMed ID: 28757262
    [No Abstract]   [Full Text] [Related]  

  • 2. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.
    Sandborn WJ; Ghosh S; Panes J; Vranic I; Su C; Rousell S; Niezychowski W;
    N Engl J Med; 2012 Aug; 367(7):616-24. PubMed ID: 22894574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct and Indirect Effects of Tofacitinib on Treatment Satisfaction in Patients with Ulcerative Colitis.
    Panés J; Su C; Bushmakin AG; Cappelleri JC; Healey P
    J Crohns Colitis; 2016 Nov; 10(11):1310-1315. PubMed ID: 27194530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes.
    Panés J; Su C; Bushmakin AG; Cappelleri JC; Mamolo C; Healey P
    BMC Gastroenterol; 2015 Feb; 15():14. PubMed ID: 25651782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tofacitinib in ulcerative colitis.
    Archer TP; Moran GW; Ghosh S
    Immunotherapy; 2016 May; 8(5):495-502. PubMed ID: 27140405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficiency comparison of tofacitinib and budesonid in treatment of nonspecific ulcerative colitis.
    Bratasiuk AM; Niroda AI
    Wiad Lek; 2017; 70(2):241. PubMed ID: 28511169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and emerging biologics for ulcerative colitis.
    Park SC; Jeen YT
    Gut Liver; 2015 Jan; 9(1):18-27. PubMed ID: 25547087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial.
    Sandborn WJ; Panés J; Zhang H; Yu D; Niezychowski W; Su C
    Gastroenterology; 2016 Jan; 150(1):96-102. PubMed ID: 26376350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tofacitinib for the treatment of ulcerative colitis.
    Izzo R; Bevivino G; Monteleone G
    Expert Opin Investig Drugs; 2016 Aug; 25(8):991-7. PubMed ID: 27177233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tofacitinib ameliorates atherosclerosis and reduces foam cell formation in apoE deficient mice.
    Wang Z; Wang S; Wang Z; Yun T; Wang C; Wang H
    Biochem Biophys Res Commun; 2017 Aug; 490(2):194-201. PubMed ID: 28601639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tofacitinib: janus bifrons in ulcerative colitis treatment.
    Peyrin-Biroulet L; Danese S
    Gastroenterology; 2013 May; 144(5):1136-8. PubMed ID: 23528660
    [No Abstract]   [Full Text] [Related]  

  • 12. Tofacitinib for the treatment of tumor necrosis factor-α inhibitor refractory esophageal Crohn's disease: a case report.
    Nathoo S; Hood WA; Keihanian S; Collinsworth AL; Glover SC
    J Med Case Rep; 2016 Sep; 10(1):264. PubMed ID: 27663846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of right dorsal ulcerative colitis in a horse.
    Simmons TR; Gaughan EM; Ducharme NG; Dill SG; King JM; Anderson WI
    J Am Vet Med Assoc; 1990 Feb; 196(3):455-8. PubMed ID: 2298678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ulcerative colitis accompanied with sarcoidosis and dermatomyositis: report of a case.
    Hayashi T; Nakamura T; Kurachi K; Asai Y; Nakajima A; Suzuki S; Konno H
    Dis Colon Rectum; 2008 Apr; 51(4):474-6. PubMed ID: 18224374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asymptomatic inflammatory bowel disease with special reference to ulcerative colitis in apparently healthy persons.
    Sakata T; Niwa Y; Goto H; Hirooka Y; Hayakawa T; Ohmiya N; Kobayashi S
    Am J Gastroenterol; 2001 Mar; 96(3):735-9. PubMed ID: 11280543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Morphological, histochemical and immunochemical characteristics of the terminal ileum of patients with ulcerative colitis. Relationship with the development of pouchitis].
    Hinojosa J; Bau I; Martínez B; García Armengol J; Roig JV; Ferrando J; Molés JR; Gómez AB; Lledó S
    Gastroenterol Hepatol; 2000; 23(6):263-8. PubMed ID: 15324620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can 99Tcm HMPAO leucocyte scintigraphy distinguish between Crohn's disease and ulcerative colitis?
    Li DJ; Freeman A; Miles KA; Wraight EP
    Br J Radiol; 1994 May; 67(797):472-7. PubMed ID: 8193894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Ulcerative colitis and polyarthritis; presentation of 3 cases including one of right regional colitis; ACTH therapy].
    JACOBS E; CAMMAERTS P; VERBANCK M; ZYLBERSZAC S
    Acta Gastroenterol Belg; 1954 Feb; 17(2):144-53. PubMed ID: 13180168
    [No Abstract]   [Full Text] [Related]  

  • 19. Acute motor sensory polyneuropathy (AMSAN) complicating active ulcerative colitis with a patchy distribution.
    Zezos P; Mpoumponaris A; Koutsopetras P; Vounotrypidis P; Molyvas E; Vadikolias K; Moschos I; Kouklakis G
    Acta Gastroenterol Belg; 2007; 70(2):226-30. PubMed ID: 17715640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines.
    Danese S; Grisham M; Hodge J; Telliez JB
    Am J Physiol Gastrointest Liver Physiol; 2016 Feb; 310(3):G155-62. PubMed ID: 26608188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.